arrow
F

Firas Hamdan

university of helsinki
H指数:14
被引数:812

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to ‘Design and in vitro validation of Brome mosaic –virus-like particles for gene delivery and immunomodulation of melanoma’ [Mater. Today Bio 36, February 2026, 102693, https://doi.org/10.1016/j.mtbio.2025.102693]

勘误:‘Brome mosaic –virus-like particles for gene delivery and immunomodulation of melanoma’的设计及体外验证 [Mater. Today Bio 36, 2026年2月, 102693, https://doi.org/10.1016/j.mtbio.2025.102693]

2026-02-050
OAAI
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response

利用葡聚糖诱导的训练免疫促进巨噬细胞的表观遗传和代谢重组,以增强结直肠癌疫苗反应

2026-01-280
OA
Novel adenovirus vaccine vectors lacking thrombosis-associated interactions with platelet factor 4

新型缺乏与血小板因子4相关血栓作用的腺病毒疫苗载体

2025-12-040
OAAI
Rates of Positive Aspiration Prior to Facial Hyaluronic Acid Filler Injections: Outcomes of a Multicenter, Cross-sectional Study

面部透明质酸填充剂注射前阳性回抽的速率:一项多中心、横断面研究的结果

2025-08-010
PRE
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses
2024-09-250
OA
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
2023-11-036
OAAI
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

叙利亚仓鼠anti-PD-L1单克隆抗体的开发使溶瘤腺病毒免疫疗法能够在免疫能力病毒复制允许的环境中进行建模

2023-02-034
OAAI
Characterization of Expanded Gamma Delta T Cells from Atypical X-SCID Patient Reveals Preserved Function and IL2RG-Mediated Signaling

来自非典型x-scid患者的扩增的 γ δ T细胞的表征揭示了保留的功能和IL2RG-Mediated信号

2022-10-193
OAAI
PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification
2021-10-0418
OAAI
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

表达增强的交叉杂交IgGA Fc PD-L1抑制剂的新型溶瘤腺病毒激活多种免疫效应子群体,从而在体外,体内和患者来源的肿瘤类器官中增强肿瘤杀伤

2021-08-0630
OAAI